Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salbutamol as a CFTR activator in adults with cystic fibrosis and residual CFTR function
NL-OMON40957Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of salbutamol in cystic fibrosis (CF), sponsored by University Medical Center Utrecht. Primary endpoints: Change in nasal potential difference and Change in sweat chloride concentration. Started May 2014; status: active, not recruiting.
02
Drugs
salbutamol
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON40957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40957.